Abstract:Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor, with no curative treatment options and median patient survival time of almost one year. Despite multi-modal therapy including surgery, irradiation and chemotherapy, all patients experience tumor progression and recurrence. Our group proposed and validated the first single cell guided functional classification of primary GBM in four tumor-intrinsic cell states which informed clinical outcome and delivered therapeutic options. However, recurrent GBM remains therapeutically unresolved due in part to the diffusely invasive nature and in part to marked cellular heterogeneity of the tumor.The evolutionary trajectory of glioblastoma after therapy is a multifaceted biological process that extends beyond discrete genetic alterations alone. Here, we profiled by multi-omics platforms the largest dataset of matched primary and recurrent GBM including 123 longitudinal glioblastoma pairs, temporally separated by standard-of-care treatment. Genomics, proteomics, and phosphoproteomics all independently captured the loss of proliferative-progenitor characteristics and a significant upregulation of specialized neuronal and synaptic signaling programs in recurrent GBM. Proteomic and phosphoproteomic analyses revealed that the molecular transition from proliferative to neuronal state at recurrence is marked by coherent post-translational activation of the WNT/PCP signaling pathway and the BRAF protein kinase. Multi-omic analysis of Patient-Derived Xenograft (PDX) models mimicked the patterns of evolutionary trajectory, consisting of marked activation of neuronal signaling programs in recurrent patients. Inhibition of the BRAF kinase with small molecule inhibitors impaired both neuronal transition and migration capability of recurrent glioblastoma cells, which are the phenotypic hallmarks of glioblastoma progression after therapy. Accordingly, combinatorial treatment of temozolomide with BRAF inhibitor, vemurafenib, significantly prolonged the survival of mouse PDX models. This work provides comprehensive insights into the biological mechanisms of glioblastoma evolution and treatment resistance and highlights new therapeutic opportunities to effectively counter them in the clinic. Citation Format: Simona Migliozzi, Kyung-Hee Kim, Harim Koo, Jun-Hee Hong, Seung Min Park, Hyung Joon Kwon, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Anna-Luisa Di Stefano, Franck Bielle, Jinlong Yin, Marc Sanson, Do-Hyun Nam, Jason K. Sa, Anna Lasorella, Jong Bae Park, Antonio Iavarone. Integrated proteogenomic characterization of longitudinal glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4638.

Progress Toward Long-Term Survivors of Glioblastoma

Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients

Radt-38. Clinical, Molecular And Imaging Features Associated With Long Term Survival In Glioblastoma Patients

Ctni-65. Determinants Of Long-Term Survival In Patients With Idh-Mutant Gliomas

Long-term survival of patients with glioblastoma multiforme (GBM)

Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma.

A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type

Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: A 1975-2018 Population-Based Study

Ten-year survival in glioblastoma. A systematic review

Biom-63. Long-Term Survival And Molecular Characterization Of Idh-Wildtype Glioblastoma In An Asian Cohort

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma

Survival analysis and associated factors of highgrade glioma patients

Molecular Characterization and Survival Analysis of a Cohort of Glioblastoma, IDH-wildtype

Abstract 4638: Integrated proteogenomic characterization of longitudinal glioblastoma

Nimg-59. Comparative Analysis Of Long-Term Glioblastoma Survivors Using Machine Learning Generated Radio-Pathomic Metrics

EPID-16. EPIDEMIOLOGICAL TRENDS FOR LONGER TERM GBM SURVIVORS POST STUPP

Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment